0001104659-26-057904
SEC filingNet loss narrowed to $2.8M on lower operating expenses, but cash burn and working capital decline underscore ongoing liquidity risk.
For the three months ended March 31, 2026, Soligenix reported a net loss of $2.8 million, compared to $3.2 million in the same period of 2025, an improvement of 12.7%. This decrease was primarily due to a reduction in operating expenses. Operating income improved 12.9% to a loss of $2.9 million from a loss of $3.3 million. Diluted earnings per share improved to $(0.28) from $(1.06), a 73.6% improvement, reflecting the lower net loss and a higher share count.
The decrease in operating expenses was primarily due to lower costs associated with third-party manufacturing, the completed Phase 2 study in Behçet's Disease (BD), and site initiation fees for the second confirmatory Phase 3 CTCL trial, partially offset by an increase in patient fees for that trial. The company continues to advance its pipeline, including a research collaboration utilizing its technology platform for filovirus and coronavirus vaccines. However, the FLASH2 trial halt will likely require a strategic reassessment of the HyBryte™ program.
The company's cash position remains constrained. Management plans to submit additional grant applications, pursue NOL sales under New Jersey's Technology Business Tax Certificate Transfer Program, and evaluate equity, royalty, and debt financing. The Rodman Sales Agreement provides a limited near-term capital source. Macroeconomic and geopolitical uncertainties are cited as additional risks to capital access. The company expects to continue generating losses in the foreseeable future, and its liquidity needs will depend largely on budgeted operational expenditures related to the advancement of its product candidates.